Despite the absence of any material news about the company for several weeks, the Kintara Therapeutics Inc (NASDAQ:KTRA) stock came into considerable focus among investors and made a strong move on Tuesday.
Yesterday, the Kintara stock delivered gains of as much as 20% and in this situation, it is perhaps important for investors to take a look at a development with regards to the company from last month. Back on September 22 the biopharmaceutical firm had made an announcement with regards to the top line data from the open label Phase 2 clinical study that had been conducted at MD Anderson Cancer Center located in Houston in Texas.
The trial in question was for the Kintara product named VAL 083 and was meant for patients suffering from glioblastoma multiforme. The results from the study were largely positive and that may be one of the reasons behind the optimism around the stock among investors at this point in time.
However, at the same time, it should be noted that the announcement had been made several weeks ago and it could, in fact, be a good idea to wait for further news with regards to Kintara before making a move.
